Prophylaxis for Pneumocystis Pneumonia in non‐HIV Immunocompromised Patients

ncbi.nlm.nih.gov March 10, 2021

prophylaxis-for-pneumocystis-pneumonia-pcp-in-non‐hiv-immunocompromised-patients

Our review shows that TMP/SMX prophylaxis is highly effective for prevention of Prophylaxis for Pneumocystis Pneumonia (PCP) in patients with hematological malignancies, bone marrow transplantation and solid organ transplantation, both for children and adults.

The overall prevalence of severe adverse events with TMP/SMX was low and did not result in treatment discontinuations.

Given the observed efficacy of TMP/SMX with regard to PCP prevention, prophylactic TMP/SMX should be considered when the risk of PCP is above the rate we observed (6.2% overall).

The PCP incidence is probably lower for most patients with solid malignancies.

Patients receiving corticosteroids for primary or metastatic brain tumours may be at a higher risk warranting prophylaxis.